Nationwide Children’s-founded advanced pathology platform Deep Lens has now raised $17.5m in all as it looks to grow its business in the clinical trial recruitment segment.
Deep Lens, a US-based advanced pathology platform developer spun out of Nationwide Children’s Hospital, closed a $14m series A round led by venture capital firm Northpond Ventures yesterday.
Northpond was joined in the round by fellow VC firms Rev1 Ventures, Sierra Ventures and Tamarind Hill.
Founded in 2017, Deep Lens has created a digital imaging platform that exploits artificial intelligence (AI) to aid clinicians in studying the causes and effect of diseases, a branch of science known as…
